We account for income taxes under SFAS No.109.
This statement requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carry forwards to the extent they are realizable.
Our effective tax rate for fiscal 2006 was 48.5% of pre-tax earnings.
This represents our normalized rate of approximately 38% increased for the in-process research and development charges recorded during the year which are not deductible for tax purposes.
Our effective tax rate for fiscal 2005 was 19% of pre-tax earnings.
This represented our normalized rate of approximately 38% reduced by a decrease in certain valuation allowances and tax reserves.
We anticipate a normalized effective tax rate of 38% of pre-tax earnings in fiscal 2007.
We had previously recorded a valuation allowance to reduce our deferred tax assets to the amount that was more likely than not to be realized.
In fiscal 2005, we considered our recent operating results, future taxable income and ongoing prudent and feasible tax planning strategies in assessing the need for the valuation allowance.
As a result, we determined that we were able to realize a portion of our deferred tax assets in excess of the net recorded amount, and therefore, an adjustment of $6.2 million was made to reduce the valuation allowance.
The benefit of the release in valuation allowance was realized through reductions to tax expense and increases to additional paid in capital.
In addition, during the fourth quarter of 2005 we received notification that the Joint Committee on Taxation had no exceptions with the Internal Revenue Service’s conclusions on several tax returns under examination.
Therefore, we released $750,000 of tax reserves related to these returns further reducing our provision for income taxes in fiscal 2005.
Segment Results of Operations Beginning in fiscal 2006, we combined our previously reported mammography and digital detector operating segments, to better reflect how we view our operations and manage our business.
In prior years, we offered DirectRay digital detectors in Hologic designed, manufactured, installed and serviced general radiography systems and also sold panels to Original Equipment Manufacturers (OEMs), to incorporate into their own equipment.
In fiscal 2006 we moved away from selling systems and panels for general radiography use and began to shift resources to our core women’s health products mammography systems.
In January 2006 we ceased sales of digital systems for general radiography, and on October 1, 2006 we ceased manufacture of general radiography panels.
As a result the primary function of the digital detector business is to support our mammography product line.
We now report our business as three segments: mammography/ breast care, osteoporosis assessment and other.
The recently acquired AEG photoconductor business is included in our other business segment.
The recently acquired R2 and Suros operations are included in mammography/breast care.
Prior periods have been restated to conform to this presentation.
The accounting policies of the segments are the same as those described in the footnotes to the accompanying consolidated financial statements.
We measure segment performance based on total revenues and operating income or loss.
Revenues from product sales of each of these segments are described in further detail above.
The discussion that follows is a summary analysis of total revenues and the primary changes in operating income or loss by segment.
Mammography/ Breast Care.
## Table 0 ##
Revenues for this business segment, which includes the mini C-arm business, domestic distribution of a third party extremity MRI system, the digital general radiography business, the conventional general radiography service business and the AEG photoconductor businesses’ increased in fiscal 2006 primarily due to the $22.1 million increase in product sales discussed above and a $1.2 million increase in service and other revenues.
The increase in product sales was primarily due to the incremental revenues as a result of the AEG acquisition as well as the initial sales of a new line of third party extremity MRI systems.
These increases were partially offset by decreases in product sales related to digital general radiography business and the conventional general radiography service business, both of which are being phased out.
The increase in service and other revenues is due to incremental revenues as a result of the AEG acquisition, increased mini C-arm and digital general radiography spare parts revenues and increased service revenues from our increased installed base of extremity MRI systems partially offset by a decrease in these revenues in the conventional general radiography business.
The decrease in operating income was primarily due to an increase in operating expenses related to the acquisition of AEG as well as purchase accounting related charges including a $1.6 million increase of cost of product sales related to the sale of inventory that had been written up to fair value as of the date of acquisition and a charge for in-process research and development of $600,000.
Also contributing to the decrease of operating income was the ramp-up of sales and marketing expenses for a new line of third party extremity MRI systems.
Fiscal Year Ended September 24, 2005 Compared to Fiscal Year Ended September 25, 2004 Product Sales.
## Table 1 ##
In fiscal 2005 our product sales increased 29% compared to fiscal 2004 primarily due to an increase in revenues from our mammography products, and to a lesser extent, an increase in osteoporosis assessment sales.
Partially offsetting these increases was a decrease in our other segment product sales, primarily attributable to our continued phase-out of our general radiography systems business.
We have discontinued taking orders for these systems but continue to service the installed base.
Mammography product sales increased 48% in fiscal 2005 compared to fiscal 2004 primarily due to a $33.5 million increase in digital mammography system sales, a $9.8 million increase in Multicare stereotactic table sales, a $6.3 million increase in digital detector sales and a $3.6 million increase in analog mammography systems sales.
The increase in our digital mammography product sales was primarily attributable to an increase in the number of Selenia systems sold in the United States and by the inclusion of the CAD software option on almost all of the units sold in the United States during the current year offset in part, by a slight decrease in the number of Selenia systems sold in Europe and a slight decrease in the average selling price for Selenia systems in fiscal 2005 as compared to fiscal 2004.
In fiscal 2005, we sold 239 digital mammography systems compared to 143 systems in fiscal 2004.
We attribute the increase in digital mammography system sales primarily to the growing acceptance of our Selenia mammography system and of digital mammography in general.
The increase in our digital detector sales reflects the increase in digital detectors sold for both general radiography and mammography.
The increase in sales of our analog mammography systems was primarily attributable to an increase in the number of systems sold internationally and for our Multicare stereotactic tables was primarily attributable to an increase in the number of systems sold worldwide in the current fiscal year compared to fiscal 2004.
PART III Item 10.
Directors and Executive Officers of the Registrant.
Pursuant to Section 406 of the Sarbanes-Oxley Act of 2002, we have adopted a Code of Ethics for Senior Financial Officers that applies to our principal executive officer and principal financial officer, principal accounting officer and controller, and other persons performing similar functions.
Our Code of Ethics for Senior Financial Officers is publicly available on our website at www.
hologic.
com.
We intend to satisfy the disclosure requirement under Item 5.05 of Current Report on Form 8-K regarding an amendment to, or waiver from, a provision of this code by posting such information on our website, at the address specified above.
The additional information required by this item is incorporated by reference to our Definitive Proxy Statement for our annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of our fiscal year.
Item 11.
Executive Compensation.
The information required by this item is incorporated by reference to our Definitive Proxy Statement for our annual meeting of stockholders to be filed with the Securities and Exchange Commission within 120 days after the close of our fiscal year.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
We maintain a number of equity compensation plans for employees, officers, directors and others whose efforts contribute to our success.
The table below sets forth certain information as of the end of our fiscal year ended September 30, 2006 regarding the shares of our common stock available for grant or granted under stock option plans and equity incentives that (i) were approved by our stockholders, and (ii) were not approved by our stockholders.
The number of securities and the exercise price of the outstanding securities have been adjusted to reflect our two-for-one stock split effected on November 30, 2005.
Equity Compensation Plan Information
## Table 2 ##
(1) Includes the following plans: 1997 Employee Equity Incentive Plan and 2000 Acquisition Equity Incentive Plan.
A description of each of these plans is as follows: 1997 Employee Equity Incentive Plan.
The purposes of the 1997 Employee Equity Incentive Plan (the “1997 Plan”), adopted by the Board of Directors in May 1997, are to attract and retain key employees, consultants and advisors, to provide an incentive for them to assist us in achieving long-range performance goals, and to enable such person to participate in our long-term growth.
In general, under the 1997 Plan, all employees,
Hologic, Inc.  Notes to Consolidated Financial Statements (continued) (In thousands, except per share data) The effective tax rate for fiscal 2009 was significantly impacted by the goodwill impairment charge recorded in the second quarter of fiscal 2009, substantially all of which is not tax deductible for tax purposes.
In addition, the tax provision for fiscal 2009 includes a reversal for a charge recorded in fiscal 2008 for approximately $2,300 related to a clarification in Massachusetts tax law on apportionment for affiliates of manufacturing companies.
The Company also recorded an additional $1,328 as a result of losing its tax holiday status due to the closure of its manufacturing facility in Shanghai, China.
The effective tax rate for fiscal 2008 was significantly impacted by the acquired in-process research and development charge related to the merger with Cytyc and Third Wave acquisition, which is not tax deductible.
The tax provision for fiscal 2008 also included a net charge of $1,498 primarily related to the Company’s U. S.  based deferred tax assets and liabilities resulting from newly enacted State legislation.
In accordance with ASC 740, the adjustment for the effect of the change in state tax law is included in the tax provision for the period that includes the enactment date.
Under ASC 740, the Company can only recognize a deferred tax asset for the future benefit of its tax loss carryforward to the extent that it is “more likely than not” that these assets will be realized.
The Company has established a valuation allowance against a portion of its remaining potential deferred tax assets after consideration of all positive and negative evidence that it is more likely than not a portion of its tax loss carryforward will not be realized.
In determining the realizability of these assets, the Company considers numerous factors, including historical profitability, estimated future taxable income and the industry in which it operates.
The valuation allowance increased $6,714 in fiscal 2009 from fiscal 2008 primarily due to the deferred taxes acquired in the Third Wave acquisition, and the Company’s belief that it is more likely than not that these state tax assets will expire unutilized.
During fiscal 2009, the Company recorded a $1,608 increase to capital in excess of par and a $1,112 decrease to goodwill related to the excess tax benefit of stock options exercised in fiscal 2009.
During fiscal 2008, the Company recorded a $13,109 increase to capital in excess of par and a $49,630 decrease to goodwill related to the excess tax benefit of stock options exercised in fiscal 2008.
As of September 26, 2009, the Company had total net operating loss and credit carryforwards of $220,391 and $10,550, respectively, that it believes are more likely than not that they will be realized.
The $220,391 excludes $359,521 of federal, state and international net operating losses, which if tax effected would be $23,362, that the Company believes will expire unutilized.
These net operating losses primarily relate to Third Wave, which was acquired in fiscal 2008.
The following table summarizes the expiration periods of the net operating loss and credit carryforwards:
## Table 3 ##
On September 30, 2007, the Company adopted Financial Accounting Standards Board (“FASB”) Interpretation (“FIN”) No.48, Accounting for Uncertainty in Income Taxes—an interpretation of FASB Statement No.109 (codified within ASC 740-10), and recorded the cumulative effect of the change in accounting principle of $480 as a decrease to opening retained earnings.

<table><tr><td></td><td colspan="6"> Years Ended</td></tr><tr><td></td><td colspan="2">September 30, 2006</td><td colspan="2">September 24, 2005</td><td colspan="2"> Change</td></tr><tr><td></td><td> Amount</td><td>% of Total Segment Revenue</td><td> Amount</td><td>% of Total Segment Revenue</td><td> Amount</td><td> %</td></tr><tr><td>Total Revenues</td><td>$335,795</td><td>100%</td><td>$189,313</td><td>100%</td><td>$146,482</td><td>77%</td></tr><tr><td>Operating Income</td><td>$44,227</td><td>13%</td><td>$17,460</td><td>9%</td><td>$26,767</td><td>153%</td></tr></table>
<table><tr><td></td><td colspan="6"> Years Ended</td></tr><tr><td></td><td colspan="2">September 24, 2005</td><td colspan="2">September 25, 2004</td><td colspan="2"> Change</td></tr><tr><td></td><td> Amount</td><td>% of Total Revenue</td><td> Amount</td><td>% of Total Revenue</td><td> Amount</td><td> %</td></tr><tr><td><i>Product Sales</i></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mammography/Breast Care</td><td>$159,469</td><td>55%</td><td>$105,906</td><td>46%</td><td>$53,563</td><td>48%</td></tr><tr><td>Osteoporosis Assessment</td><td>$56,065</td><td>20%</td><td>$51,376</td><td>23%</td><td>$4,689</td><td>9%</td></tr><tr><td>Other</td><td>$13,541</td><td>5%</td><td>$20,654</td><td>9%</td><td>-$7,113</td><td>-34%</td></tr><tr><td></td><td>$229,075</td><td>80%</td><td>$177,936</td><td>78%</td><td>$51,139</td><td>29%</td></tr></table>
<table><tr><td>Plan Category</td><td>Number Of Securities To Be Issued Upon Exercise Of Outstanding Options, Warrants And Rights (a)</td><td>Weighted-Average Exercise Price Of OutstandingOptions, Warrants And Rights (b)</td><td>Number Of Securities Remaining Available For Future Issuance Under Equity Compensation Plans (excluding securities reflected in column (a)) (c)</td></tr><tr><td>Equity compensation plans approved by security holders</td><td>3,650,734</td><td>$16.85</td><td>32,014</td></tr><tr><td>Equity compensation plans not approved by security holders -1</td><td>567,331</td><td>$6.94</td><td>0</td></tr><tr><td>Total</td><td>4,218,065</td><td>$15.52</td><td>32,014</td></tr></table>
<table><tr><td rowspan="2"></td><td colspan="6"> Period of Expiration</td></tr><tr><td> 2010-2015</td><td> 2016-2020</td><td> 2021-2025</td><td> 2026-2030</td><td> No expiration</td><td> Total</td></tr><tr><td>Net operating loss</td><td>$682</td><td>$21,289</td><td>$102,543</td><td>$95,877</td><td>$—</td><td>$220,391</td></tr><tr><td>R&D credit</td><td>$90</td><td>$2,426</td><td>$3,593</td><td>$24</td><td>$—</td><td>$6,133</td></tr><tr><td>CA Credits</td><td>$—</td><td>$—</td><td>$—</td><td>$—</td><td>$1,273</td><td>$1,273</td></tr><tr><td>CT credit</td><td>$—</td><td>$823</td><td>$424</td><td>$—</td><td>$—</td><td>$1,247</td></tr><tr><td>MA credits</td><td>$—</td><td>$719</td><td>$805</td><td>$—</td><td>$—</td><td>$1,524</td></tr><tr><td>WI credits</td><td>$—</td><td>$—</td><td>$221</td><td>$—</td><td>$—</td><td>$221</td></tr><tr><td>IN credits</td><td>$—</td><td>$—</td><td>$—</td><td>$—</td><td>$152</td><td>$152</td></tr></table>

Question: What was the total amount of Period of Expiration in the range of 200 and 500 in 2021-2025?
Answer: 645.0